Until recently, lenvatinib, a multityrosinekinase inhibitor, was recommended as the first-line therapy for most patientsdiagnosed with RAI-refractory thyroid cancer (18,29).However, currently, the European Society for Medical Oncology (ESMO) and theNational Comprehensive Cancer Network (NCCN) recognize the importance of somaticgenome analysis, including BRAF V600E mutation screening, in patients diagnosed withRAI-refractory thyroid cancer and recommend combination therapy with dabrafenib andtrametinib in patients harboring this mutation (30). The gene discussed is BRAF; the disease is thyroid gland carcinoma.